Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma

NCT02107950 is registered in ClinicalTrials.gov with SOTIO a.s. as lead sponsor.

NCT NCT02107950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma
Lead sponsor
SOTIO a.s.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
May 17, 2017
Enrollment
71 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer (ovca), ovarian epithelial cancer, ovarian neoplasms